Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.
BOSTON (TheStreet) -- For a brief moment, and mostly on Twitter, Gilead Sciences
was buying Achillion Pharmaceuticals
The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead...
After Thursday’s trading in Achillion Pharmaceuticals, Inc. (ACHN) MarketIntelligenceCenter.com's option trade-picking algorithms uncovered a trade that offers a 14.38% or 18.74% (for comparison purposes only), while providing 40.12% downside...
In a report published Thursday, JMP Securities analysts expressed their views on Biotechnology stocks after the EASL abstracts were made available ahead of the European liver meeting. The analysts have a Market Perform rating on Merck & Co. Inc...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):